Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

APALOZ 20 MG COMPRIMIDOS BUCODISPERSABLES - CIMA-AEMPS Drug Approval Details

Approvals/CIMA-AEMPS/APALOZ 20 MG COMPRIMIDOS BUCODISPERSABLES

Approved

STANDARD

APALOZ 20 MG COMPRIMIDOS BUCODISPERSABLES

Laboratorios Alter S.A.🇪🇸 Spanish Agency of Medicines and Medical Devices

Approval Date: Feb 10, 2023
Approval ID: b7b39d81752501bb
Company: Laboratorios Alter S.A.
Type: Standard

Approval Details

Approval Id: b7b39d81752501bb
Drug Cima Aemps Name: APALOZ 20 MG COMPRIMIDOS BUCODISPERSABLES
Register Number: 88624
Holder Company Name: Laboratorios Alter S.A.
Marketing Company Name: Laboratorios Alter S.A.
Authorization Date: 2023-02-10
Dosage Form: COMPRIMIDO BUCODISPERSABLE
Dose: 20 mg
Route Of Administration: VÍA ORAL
Prescription Type: Medicamento Sujeto A Prescripción Médica
Commercialized: Yes
Company Name: Laboratorios Alter S.A.

Active Ingredients

ARIPIPRAZOL

20 mg

Approved

Quick Info

Agency

CIMA-AEMPS

Country

🇪🇸

Approval Date

Feb 10, 2023

Approval ID

b7b39d81752501bb

Type

Standard

Back to CIMA-AEMPS Approvals